Bi
Biocon Biologics
Bangalore INFounded 20195,000 employees
Private CapbiotechPrivateOncologyImmunology
Platform: Biosim Global
Market Cap
N/A
All Drugs
2
Clinical Trials
5
Failed / Terminated
4
FDA Approved
1
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| BIO-2612 | BIO-2612 | Phase 1 | 2 | SMN2 | Celiac | ||
| Lisotinib | BIO-1067 | Approved | 3 | SGLT2 | LN |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (1)